Is TARS a Buy? What to Consider in 2026
Short answer
The bull case for Tarsus Pharmaceuticals (TARS) rests on XDEMVY prescription growth: XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. Revenue (TTM) is ~$540M. If you believe that thesis holds, the real questions become position sizing and overlap, not timing. The main risk to that view: The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. Whether TARS is a buy comes down to whether you believe the thesis. This is informational, not a recommendation, and Walnut is not an investment adviser.
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care. Its business is anchored by XDEMVY (lotilaner ophthalmic solution 0.25%), the first and only FDA-approved treatment that directly targets the Demodex mites behind Demodex blepharitis, a common and previously under-treated eyelid condition. The company delivered roughly 400,000 bottles of XDEMVY in 2025 (up from about 163,000 in 2024) and is building a lotilaner-based pipeline that includes TP-04 for ocular rosacea and TP-05 for potential prevention of Lyme disease, with topline data for both expected in the first half of 2027. The investment picture is a classic single-product growth story. XDEMVY net product sales grew more than 85% year over year in the first quarter of 2026, gross margins run around 93%, and management targets more than $2 billion in eventual peak sales, yet the company still runs near breakeven and depends heavily on one drug. In late June 2026, short-seller Culper Research disclosed a short position and alleged that XDEMVY sales lean on an improper Medicare copay-assistance arrangement and that the addressable market is far smaller than the company claims, which added a new layer of controversy on top of the usual biopharma reimbursement and competition risks.
What's the case for buying TARS?
1. XDEMVY prescription growth
XDEMVY net product sales rose more than 85% year over year in Q1 2026 to about $145 million, driven by expanding prescriber adoption and direct-to-consumer campaigns. Management reaffirmed full-year 2026 guidance of roughly $670 to $700 million in net product sales. The core question is how long high double-digit growth can persist as the easiest-to-reach prescribers are converted.
2. Large, under-penetrated indication
Demodex blepharitis is estimated to affect tens of millions of Americans, and XDEMVY remains the only FDA-approved therapy that targets the underlying mites. Tarsus frames a path to more than $2 billion in peak sales on the back of that penetration runway. A short-seller has publicly disputed the size of the realistic addressable market, so this driver is also contested.
3. High-margin economics
XDEMVY carries gross margins around 93%, and the Q1 2026 net loss narrowed sharply to about $7 million from roughly $25 million a year earlier as revenue scaled against a largely fixed commercial base. If growth continues without a matching rise in selling and marketing spend, operating leverage could push the company toward sustained profitability.
4. Pipeline optionality
Beyond XDEMVY, Tarsus is advancing TP-04 for ocular rosacea and TP-05, an oral tablet studied for Lyme disease prevention, both using the same lotilaner molecule. Topline data for these Phase 2 programs is expected in the first half of 2027. Success would diversify a currently one-product company, though these are early-stage and carry standard clinical risk.
What are the risks to TARS?
The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set.
How is TARS valued? (as of JULY 2026)
Snapshot for TARS as of July 2026, sourced from Yahoo Finance and may be delayed. Valuation figures move with price and earnings; verify the current numbers with your broker before deciding.
- Revenue (TTM): ~$540M
- XDEMVY sales (FY2025): ~$451M
- Q1 2026 revenue: ~$162M
- FY2026 sales guidance: ~$670-700M
- Market cap: ~$2.9B
- Cash & marketable securities: ~$417M
As of July 2026 TARS traded near $67 with a market capitalization around $2.9 billion, valuing the company at several times trailing revenue on a still-unprofitable base. That multiple reflects expectations of continued high XDEMVY growth toward the company's stated peak-sales ambitions. The recent short-seller report contributed to share-price volatility and directly challenges the growth and market-size assumptions embedded in the valuation.
How do you decide if TARS is a buy?
Rather than asking whether TARS is a buy in the abstract, it tends to help to answer four questions:
- Thesis: do you believe the case above, and is it still true today?
- Time horizon: a single stock can be volatile, so a longer horizon absorbs more of the swings.
- Position sizing: a thesis can be right and the sizing still wrong; decide how much of your portfolio one name should be.
- Overlap: check whether you already hold TARS indirectly through an index or sector ETF before adding more.
For the full picture, see the TARS stock guide (what the company does, the ETFs that hold it, similar stocks, and the themes it fits). In Walnut you can ask its AI about TARS against your real portfolio and see your actual exposure before deciding.
The bottom line on TARS
The bottom line: Tarsus Pharmaceuticals's story right now is XDEMVY prescription growth, with revenue (ttm) at ~$540M. If you believe that narrative continues, the call is about sizing TARS sensibly and checking overlap with what you own; if you doubt it (the risk: the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company.), it is not for you. Decide from the thesis, not the ticker. Walnut is not an investment adviser.
Build a basket around TARS with Walnut
Use Tarsus Pharmaceuticals as one constituent in a thematic basket Walnut's AI helps you assemble. Describe a thesis you believe in, the AI proposes the holdings and weights, and you approve before any broker order.
FAQ
Is TARS a good stock to buy right now?
+
The case for Tarsus Pharmaceuticals right now is XDEMVY prescription growth, with revenue (ttm) at ~$540M. If you believe that thesis holds, TARS is a way to own it and the real questions are sizing and overlap, not timing; the main risk to that view is the overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. So it comes down to whether you believe the thesis. Walnut is not an investment adviser and this is not a recommendation.
What does Tarsus Pharmaceuticals do?
+
Tarsus Pharmaceuticals is a commercial-stage biopharmaceutical company focused on therapeutic eye care.
What are the main risks of TARS?
+
The overwhelming risk is single-product concentration: essentially all revenue comes from XDEMVY, so any slowdown in prescriptions, coverage, or pricing hits the whole company. In late June 2026, short-seller Culper Research alleged that XDEMVY sales depend on donations routed to a blepharitis copay fund in a way it argues may violate the federal Anti-Kickback Statute, and it claimed the true addressable market is roughly a fifth of company estimates; these are unproven allegations, but they introduce regulatory, reimbursement, and reputational uncertainty. Tarsus also depends on intellectual property licensed from Elanco, faces gross-to-net and Medicare Part D dynamics that can compress net pricing, and still runs near breakeven with a history of losses. Cheaper off-label alternatives and potential future competitors, plus binary Phase 2 pipeline readouts, round out the risk set.
What does Tarsus Pharmaceuticals do?
+
Tarsus is a commercial-stage biopharmaceutical company focused on eye care. Its main product, XDEMVY, is the first FDA-approved treatment for Demodex blepharitis, a common eyelid condition caused by mites. It is also developing lotilaner-based candidates for ocular rosacea and Lyme disease prevention.
How does Tarsus make money?
+
Almost all revenue comes from XDEMVY net product sales, supplemented by smaller license and collaboration revenue. In Q1 2026 the company reported about $162 million in total revenue, of which roughly $145 million was XDEMVY. Full-year 2025 XDEMVY sales were about $451 million.
Is Tarsus Pharmaceuticals profitable?
+
Not consistently. The company has a history of losses, though its Q1 2026 net loss narrowed to about $7 million from roughly $25 million a year earlier as XDEMVY revenue scaled against high (about 93%) gross margins. Whether it reaches sustained profitability depends on continued growth versus commercial spending.
What is XDEMVY and why does it matter to the stock?
+
XDEMVY (lotilaner ophthalmic solution) is the only FDA-approved drug that targets the Demodex mites behind Demodex blepharitis. It generates essentially all of Tarsus's revenue, so the stock's direction is closely tied to XDEMVY prescription growth, reimbursement, and peak-sales potential.
Walnut is informational and is not an investment adviser. This page is educational and not a recommendation to buy or sell TARS; figures are approximate and dated, and your own situation, time horizon, and risk tolerance should drive any decision. Verify current data before investing.